Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with essential hypertension
Patients with a BMI \> 25 kg/m2
Patients with LVH (LVWT ≥ 1.3 cm) confirmed by the ECHO
You may not be if
Patients treated with an ACE or an ARB within 3 months of study entry (Study Visit 1) who are unable or unwilling to undergo the 3 month washout period.
Patients treated with an ACE and ARB combination at study entry.
Known secondary hypertension of any etiology (e.g., uncorrected renal artery stenosis).
Clareo Health | Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension
